



Adjuvant Immunotherapy in Resected Cutaneous Melanoma: Current Guideline Recommendations¹



Full abbreviations, accreditation, and disclosure information available at [PeerView.com/WUW40](https://www.peerview.com/WUW40)

	Nivolumab (Anti-PD-1)	Pembrolizumab (Anti-PD-1)	Dabrafenib + Trametinib (BRAF/MEK) BRAF V600 Mutated
Stage IIIA-D sentinel node positive	Preferred	Preferred	Preferred
Stage III clinical node positive	Category 1 recommendation	Category 1 recommendation	Category 1 recommendation
Stage III in transit	Category 1 recommendation	Preferred	Preferred
Stage IV resected (NED)	Category 1 recommendation <i>Adjuvant nivolumab + ipilimumab is recommended (category 2B)</i>	Preferred	Recommended (category 2B) <i>Other BRAF/MEK combinations are also recommended (category 2B)</i>

1. NCCN Clinical Practice Guidelines in Oncology. Melanoma: Cutaneous. Version 2.2022. https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf.



Adjuvant Immunotherapy in Resected Cutaneous Melanoma: Current Dosing Recommendations



Full abbreviations, accreditation, and disclosure information available at [PeerView.com/WUW40](https://www.peerview.com/WUW40)

Adjuvant therapy

Nivolumab¹ (Anti-PD-1)

240 mg every 2 weeks or
480 mg every 4 weeks
(FDA approved)

Pembrolizumab² (Anti-PD-1)

200 mg every 3 weeks or
400 mg every 6 weeks;
2 mg/kg (up to 200 mg)
every 3 weeks for pediatric
patients (FDA approved)

Dabrafenib + Trametinib^{3,4} (BRAF/MEK) BRAF V600 Mutated

Dabrafenib: 150 mg
orally twice daily
Trametinib: 2 mg
orally once daily
(FDA approved)

Neoadjuvant Immunotherapy

In clinical trials, flipped
dosing (2x ipilimumab
1 mg/kg + nivolumab
3 mg/kg) has been
shown to be a safe and
effective strategy in
melanoma settings⁵

New Developments in Adjuvant Therapy
Based on the KEYNOTE-716 trial,
pembrolizumab is now approved for the
adjuvant treatment of stage IIB/C melanoma
following complete resection⁶

Dosing in the KEYNOTE-716 trial:
200 mg IV every 3 weeks or 2 mg/kg
(pediatric patients) for up to 17 cycles⁷

1. Opdivo (nivolumab) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125554s0901bl.pdf. 2. Keytruda (pembrolizumab) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125514s0961bl.pdf.

3. Tafinlar (dabrafenib) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s0081bl.pdf. 4. Mekinist (trametinib) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204114s0071bl.pdf.

5. Rozeman EA et al. *Lancet Oncol.* 2019;20:948-960. 6. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-adjuvant-treatment-stage-iib-ic-melanoma>. 7. Luke J et al. European Society for Medical Oncology Congress 2021 (ESMO 2021). Abstract LBA3_PR.